Maravai Lifesciences Holdings (MRVI) Total Debt (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Total Debt of $246.5 million for Q1 2026, down 16.44% year-over-year from $294.9 million in Q1 2025, and down 15.53% quarter-over-quarter from $291.8 million in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Total Debt (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Total Debt history runs 7 years deep, the most recent figure standing at $246.5 million for Q1 2026.
- In Q1 2026, Total Debt fell 16.44% year-over-year to $246.5 million; the TTM figure through Mar 2026 stood at $246.5 million (down 16.44% YoY), while the FY2025 annual figure was $291.8 million, down 3.19% from the prior year.
- Total Debt for Q1 2026 stood at $246.5 million, down from $291.8 million in the prior quarter.
- The five-year high for Total Debt was $746.0 million in Q2 2022, with the low at $246.5 million in Q1 2026.
- The 5-year median for Total Debt is $523.3 million (2024), against an average of $476.9 million.
- The sharpest annual moves came in 2022 and 2025: Total Debt soared 40.07% in 2022, then slumped 43.87% in 2025.
- Maravai Lifesciences Holdings' Total Debt stood at $527.4 million in 2022, then advanced by 0.41% to $529.6 million in 2023, then sank by 43.09% to $301.4 million in 2024, then fell by 3.19% to $291.8 million in 2025, then dropped by 15.53% to $246.5 million in 2026.
- Business Quant data shows MRVI's Total Debt at $246.5 million in Q1 2026, $291.8 million in Q4 2025, and $292.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | 148.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 148.23 Mn |
| Mar 31, 2026 | 246.45 Mn |
| Dec 31, 2025 | 291.77 Mn |
| Sep 30, 2025 | 292.82 Mn |
| Jun 30, 2025 | 293.88 Mn |
| Mar 31, 2025 | 294.94 Mn |
| Dec 31, 2024 | 301.37 Mn |
| Sep 30, 2024 | 521.72 Mn |
| Jun 30, 2024 | 522.52 Mn |
| Mar 31, 2024 | 523.33 Mn |
| Dec 31, 2023 | 529.59 Mn |
| Sep 30, 2023 | 524.96 Mn |
| Jun 30, 2023 | 525.78 Mn |
| Mar 31, 2023 | 682.83 Mn |
| Dec 31, 2022 | 527.44 Mn |
| Sep 30, 2022 | 716.67 Mn |
| Jun 30, 2022 | 745.98 Mn |
| Mar 31, 2022 | 564.69 Mn |
| Dec 31, 2021 | 565.43 Mn |
| Sep 30, 2021 | 526.88 Mn |